ABT-751 With Chemotherapy for Relapsed Pediatric ALL
A Phase I/II Trial of ABT-751 Combined With Dexamethasone, PEG-asparaginase, and Doxorubicin in Relapsed Acute Lymphoblastic Leukemia (ALL)
Study Overview
Status
Conditions
Detailed Description
All patients will receive the 2 courses of chemotherapy unless medical complications prevent the administration of some of the drugs. Treatment for the first 2 courses of therapy will last about 2 months.
Treatment on this study will consist of a combination of 8 anti-cancer medications. The 8 anticancer medicines are ABT-751, dexamethasone, PEG-asparaginase, doxorubicin, cytarabine (Ara-C), methotrexate (MTX), cyclophosphamide, and 6-thioguanine. All the drugs except ABT-751 are well known anti-cancer drugs and have been used extensively in the treatment of cancer.
During the Phase I portion of this study, when you enroll, you will be given an assigned dose of ABT-751. The dose of ABT-751 will be based on doses given in previous studies done with adults and children. At each dose level of ABT-751, between 3 and 6 children will receive ABT-751 in combination with chemotherapy. If the side effects are not too severe, the next group of children will receive a higher dose. The dose will continue to be increased until we find the dose that causes serious side effects. Your dose of ABT-751 will not be increased. If you have bad side effects, your dose may be decreased.
The dose used during the Phase 2 part of this study will be determined by the outcome of the Phase I study. The highest dose used in Phase I that was tolerated without serious side effects will be the one used in Phase 2.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90027
- Childrens Hospital Los Angeles
-
Palo Alto, California, United States, 94304-1812
- Stanford University Medical Center
-
San Francisco, California, United States, 94143-0106
- UCSF School of Medicine
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109-0914
- C.S. Mott Children's Hospital
-
-
Washington
-
Seattle, Washington, United States, 98105
- Seattle Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Age Patients must be < 21 years of age when enrolled onto this study. T2005-001 Protocol version 6/27/2007 17
Diagnosis
Patients must have relapsed or refractory ALL with a M3 marrow (marrow blasts >25%) without clinical evidence of testicular disease or laboratory evidence of CNS disease defined as CSF WBC > 5 cells/microliter and blasts. (See Appendix I for method of evaluating traumatic lumbar punctures.) Patients in early first relapse (defined as a patient who relapses less than 36 months from their initial remission [CR1]) are eligible for the phase I portion of the trial.
- Performance Level Karnofsky > 60% for patients > 10 years of age and Lansky > 60% for patients < 10 years of age.
Prior Therapy Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.
- Prior anthracycline exposure: Patients must have less than 300mg/m2 lifetime exposure of anthracycline chemotherapy. (See Appendix III for calculation criteria)
- Stem Cell Transplant (SCT): Patients are eligible 6 months after allogeneic stem cell transplant as long as patients are not actively being treated for graft-versus-host-disease (GvHD).
- During the phase I portion of the trial, there is no limit on the number of prior treatment regimens.
During the phase II portion of the trial, patients must have had two or more prior therapeutic attempts defined as:
- Persistent initial disease after two induction attempts, or
- Relapse after one-reinduction attempt (2nd relapse), or
- Persistent disease after first relapse and initial re-induction attempt (Patients in any first relapse are not eligible for the phase II portion of the study)
- During the phase II portion of the trial, patients must have no more than 3 prior therapeutic attempts and it must be at least 6 months since the last treatment with a "VPLD" induction/re-induction regimen.
Reproductive Function
- Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed prior to enrollment and within 48 hours of starting therapy.
- Female patients with infants must agree not to breastfeed their infants while on this study.
- Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study and for 3 months following completion of therapy.
Exclusion Criteria
Drug Allergies
Patients will be excluded if they have allergies to the following drugs:
- Asparaginase products
- Sulfa containing medications
- Renal Function Patients will be excluded if their serum creatinine is > the upper limit of normal (ULN) for age at the institution's laboratory.
Liver/Pancreatic Function
- Direct bilirubin > 1.5x the institutional ULN for age. A total bilirubin result that is less than 1.5 times the institutional ULN for age may be used for eligibility if a direct bilirubin result is not available.
- SGPT (ALT) > 4 x institutional ULN
- Grade 3 or greater pancreatitis as defined by the CTCAE v3.0
- Amylase or Lipase > 2 x institutional ULN
- Cardiac Function Patients will be excluded if their shortening fraction by echocardiogram is less than 30%.
Infection Patients will be excluded if they have an active, uncontrolled infection.
- Patients with grade 2 or greater motor or sensory neuropathy per CTC 3.0 criteria.
- Patients with grade 2 or greater Ileus (neuroconstipation) per CTC 3.0 criteria.
- Patients currently being treated with coumadin.
- Patients currently being treated with colchicines.
- Patients planning on receiving other investigational agents while on this study. (An investigational agent is defined as any drug not currently approved for use in humans.)
- Patients planning on receiving other anti-cancer therapies while on this study.
- Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.
- Patients who, based on BSA and current dose level, require a daily dose of ABT-751 that is less than 25mg per day.
- Patients who have started protocol therapy prior to enrollment. Patient may still enroll if IT Ara-C or IT MTX were given within 48 hours of study enrollment as part of the diagnostic lumbar procedure. These patients will not participate in the CSF PK portion of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Dose Level 1
Treatment Dose of ABT-751 is 80 mg/m2/day Tx Course 1: • ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate Tx Course 2: • Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751 Tx Courses 3-12 (maintenance courses): • ABT-751, IT Methotrexate |
Treatment Course 1: Oral capsule to be given daily for 21 days at assigned dose. Treatment Course 2: ABT-751 will be taken once daily, by mouth, at the assigned dose on days 15-35. Treatment Course 3: ABT-751 will be taken once daily, by mouth, at the assigned dose on days 1-21 followed by 1 week of rest.
Other Names:
In Treatment Course 1 only:
Other Names:
In Treatment Course 1:
In Treatment Course 2:
Other Names:
In Treatment Course 1 only: • 60 mg/m2/day IV over 15 minutes on day 1.
Other Names:
In Treatment Course 2: • 75 mg/m2/day IV on days 2 through 5 and days 9 through 12.
Other Names:
In Treatment Course 1: • Given Intrathecally on day 15 at the dose defined by age below.
In Treatment Course 2: • Given Intrathecally on day 1, 8, 15 and 22 at the dose defined by age below.
In Treatment Course 3: Intrathecally on day 1 at the age-defined dose
Other Names:
Course 2 only: • 1000mg/m2/day IV over 30 minutes to be given on day 1.
Other Names:
Treatment Course 2 only: • 60 mg/m2/day to be given orally on days 1 through 14.
Other Names:
|
|
Experimental: Dose Level 2
Treatment Dose of ABT-751 is 100 mg/m2/day Tx Course 1: • ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate Tx Course 2: • Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751 Tx Courses 3-12 (maintenance courses): • ABT-751, IT Methotrexate |
Treatment Course 1: Oral capsule to be given daily for 21 days at assigned dose. Treatment Course 2: ABT-751 will be taken once daily, by mouth, at the assigned dose on days 15-35. Treatment Course 3: ABT-751 will be taken once daily, by mouth, at the assigned dose on days 1-21 followed by 1 week of rest.
Other Names:
In Treatment Course 1 only:
Other Names:
In Treatment Course 1:
In Treatment Course 2:
Other Names:
In Treatment Course 1 only: • 60 mg/m2/day IV over 15 minutes on day 1.
Other Names:
In Treatment Course 2: • 75 mg/m2/day IV on days 2 through 5 and days 9 through 12.
Other Names:
In Treatment Course 1: • Given Intrathecally on day 15 at the dose defined by age below.
In Treatment Course 2: • Given Intrathecally on day 1, 8, 15 and 22 at the dose defined by age below.
In Treatment Course 3: Intrathecally on day 1 at the age-defined dose
Other Names:
Course 2 only: • 1000mg/m2/day IV over 30 minutes to be given on day 1.
Other Names:
Treatment Course 2 only: • 60 mg/m2/day to be given orally on days 1 through 14.
Other Names:
|
|
Experimental: Dose Level 3
Treatment Dose of ABT-751 is 125 mg/m2/day Tx Course 1: • ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate Tx Course 2: • Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751 Tx Courses 3-12 (maintenance courses): • ABT-751, IT Methotrexate |
Treatment Course 1: Oral capsule to be given daily for 21 days at assigned dose. Treatment Course 2: ABT-751 will be taken once daily, by mouth, at the assigned dose on days 15-35. Treatment Course 3: ABT-751 will be taken once daily, by mouth, at the assigned dose on days 1-21 followed by 1 week of rest.
Other Names:
In Treatment Course 1 only:
Other Names:
In Treatment Course 1:
In Treatment Course 2:
Other Names:
In Treatment Course 1 only: • 60 mg/m2/day IV over 15 minutes on day 1.
Other Names:
In Treatment Course 2: • 75 mg/m2/day IV on days 2 through 5 and days 9 through 12.
Other Names:
In Treatment Course 1: • Given Intrathecally on day 15 at the dose defined by age below.
In Treatment Course 2: • Given Intrathecally on day 1, 8, 15 and 22 at the dose defined by age below.
In Treatment Course 3: Intrathecally on day 1 at the age-defined dose
Other Names:
Course 2 only: • 1000mg/m2/day IV over 30 minutes to be given on day 1.
Other Names:
Treatment Course 2 only: • 60 mg/m2/day to be given orally on days 1 through 14.
Other Names:
|
|
Experimental: Dose Level 4
Treatment Dose of ABT-751 is 150 mg/m2/day Tx Course 1: • ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate Tx Course 2: • Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751 Tx Courses 3-12 (maintenance courses): • ABT-751, IT Methotrexate |
Treatment Course 1: Oral capsule to be given daily for 21 days at assigned dose. Treatment Course 2: ABT-751 will be taken once daily, by mouth, at the assigned dose on days 15-35. Treatment Course 3: ABT-751 will be taken once daily, by mouth, at the assigned dose on days 1-21 followed by 1 week of rest.
Other Names:
In Treatment Course 1 only:
Other Names:
In Treatment Course 1:
In Treatment Course 2:
Other Names:
In Treatment Course 1 only: • 60 mg/m2/day IV over 15 minutes on day 1.
Other Names:
In Treatment Course 2: • 75 mg/m2/day IV on days 2 through 5 and days 9 through 12.
Other Names:
In Treatment Course 1: • Given Intrathecally on day 15 at the dose defined by age below.
In Treatment Course 2: • Given Intrathecally on day 1, 8, 15 and 22 at the dose defined by age below.
In Treatment Course 3: Intrathecally on day 1 at the age-defined dose
Other Names:
Course 2 only: • 1000mg/m2/day IV over 30 minutes to be given on day 1.
Other Names:
Treatment Course 2 only: • 60 mg/m2/day to be given orally on days 1 through 14.
Other Names:
|
|
Experimental: Dose Level 5
Treatment Dose of ABT-751 is 175 mg/m2/day Tx Course 1: • ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate Tx Course 2: • Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751 Tx Courses 3-12 (maintenance courses): • ABT-751, IT Methotrexate |
Treatment Course 1: Oral capsule to be given daily for 21 days at assigned dose. Treatment Course 2: ABT-751 will be taken once daily, by mouth, at the assigned dose on days 15-35. Treatment Course 3: ABT-751 will be taken once daily, by mouth, at the assigned dose on days 1-21 followed by 1 week of rest.
Other Names:
In Treatment Course 1 only:
Other Names:
In Treatment Course 1:
In Treatment Course 2:
Other Names:
In Treatment Course 1 only: • 60 mg/m2/day IV over 15 minutes on day 1.
Other Names:
In Treatment Course 2: • 75 mg/m2/day IV on days 2 through 5 and days 9 through 12.
Other Names:
In Treatment Course 1: • Given Intrathecally on day 15 at the dose defined by age below.
In Treatment Course 2: • Given Intrathecally on day 1, 8, 15 and 22 at the dose defined by age below.
In Treatment Course 3: Intrathecally on day 1 at the age-defined dose
Other Names:
Course 2 only: • 1000mg/m2/day IV over 30 minutes to be given on day 1.
Other Names:
Treatment Course 2 only: • 60 mg/m2/day to be given orally on days 1 through 14.
Other Names:
|
|
Experimental: Dose Level 0
Treatment Dose of ABT-751 is 65 mg/m2/day Tx Course 1: • ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate Tx Course 2: • Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751 Tx Courses 3-12 (maintenance courses): • ABT-751, IT Methotrexate |
Treatment Course 1: Oral capsule to be given daily for 21 days at assigned dose. Treatment Course 2: ABT-751 will be taken once daily, by mouth, at the assigned dose on days 15-35. Treatment Course 3: ABT-751 will be taken once daily, by mouth, at the assigned dose on days 1-21 followed by 1 week of rest.
Other Names:
In Treatment Course 1 only:
Other Names:
In Treatment Course 1:
In Treatment Course 2:
Other Names:
In Treatment Course 1 only: • 60 mg/m2/day IV over 15 minutes on day 1.
Other Names:
In Treatment Course 2: • 75 mg/m2/day IV on days 2 through 5 and days 9 through 12.
Other Names:
In Treatment Course 1: • Given Intrathecally on day 15 at the dose defined by age below.
In Treatment Course 2: • Given Intrathecally on day 1, 8, 15 and 22 at the dose defined by age below.
In Treatment Course 3: Intrathecally on day 1 at the age-defined dose
Other Names:
Course 2 only: • 1000mg/m2/day IV over 30 minutes to be given on day 1.
Other Names:
Treatment Course 2 only: • 60 mg/m2/day to be given orally on days 1 through 14.
Other Names:
|
|
Experimental: Dose Level -1
Treatment Dose of ABT-751 is 50 mg/m2/day Tx Course 1: • ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate Tx Course 2: • Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751 Tx Courses 3-12 (maintenance courses): • ABT-751, IT Methotrexate |
Treatment Course 1: Oral capsule to be given daily for 21 days at assigned dose. Treatment Course 2: ABT-751 will be taken once daily, by mouth, at the assigned dose on days 15-35. Treatment Course 3: ABT-751 will be taken once daily, by mouth, at the assigned dose on days 1-21 followed by 1 week of rest.
Other Names:
In Treatment Course 1 only:
Other Names:
In Treatment Course 1:
In Treatment Course 2:
Other Names:
In Treatment Course 1 only: • 60 mg/m2/day IV over 15 minutes on day 1.
Other Names:
In Treatment Course 2: • 75 mg/m2/day IV on days 2 through 5 and days 9 through 12.
Other Names:
In Treatment Course 1: • Given Intrathecally on day 15 at the dose defined by age below.
In Treatment Course 2: • Given Intrathecally on day 1, 8, 15 and 22 at the dose defined by age below.
In Treatment Course 3: Intrathecally on day 1 at the age-defined dose
Other Names:
Course 2 only: • 1000mg/m2/day IV over 30 minutes to be given on day 1.
Other Names:
Treatment Course 2 only: • 60 mg/m2/day to be given orally on days 1 through 14.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Patients That Experienced Dose Limiting Toxicity From ABT-751
Time Frame: Each dose level is evaluated
|
ABT-751 was given daily for 21 days for a period of 28 day course in combination with dexamethasone, PEG-asparaginase, and doxorubicin. The occurrence of a dose limiting toxicity (DLT) was evaluated at the end of the 28 day course. DLT will be defined as any of the following events that are deemed by the investigator as probably or definitely attributable to ABT-751. Toxicity grade follows the CTCAE criteria, version 3.0. A copy of the CTCAE can be downloaded from the CTEP home page (http://ctep.cancer.gov).
|
Each dose level is evaluated
|
|
Number of Patients That Achieved Complete Response to ABT-751
Time Frame: Day 29 of Course 1
|
Complete response (CR) is the occurrence of all of the following on approximately Day 29: less than 5% leukemic blasts in the bone marrow aspirate with no evidence of leukemic blasts in the CSF or peripheral blood and recovery of peripheral blood counts of an Absolute neutrophil count (ANC) > 750/μL and Platelet count > 75,000 μL.
|
Day 29 of Course 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Patients With Occurrence of Toxic Death
Time Frame: From the first dose of study therapy until 30 days after last therapy dose. Last dose protocol therapy is on day 21.
|
The occurrence of toxic death at anytime that is definitely, probably or possibly related to the treatment.
|
From the first dose of study therapy until 30 days after last therapy dose. Last dose protocol therapy is on day 21.
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Paul S Gaynon, MD, Childrens Hospital Los Angeles, Therapeutic Advances in Childhood Leukemia Consortium
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Leukemia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Lymphoid
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiviral Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Dermatologic Agents
- Antibiotics, Antineoplastic
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Dexamethasone
- Cyclophosphamide
- Doxorubicin
- Cytarabine
- Methotrexate
- Asparaginase
- Mercaptopurine
- Thioguanine
- Pegaspargase
Other Study ID Numbers
- T2005-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Lymphoblastic Leukemia
-
National Cancer Institute (NCI)Active, not recruitingAcute Lymphoblastic Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia | Adult T Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Adult L1 Acute Lymphoblastic Leukemia | Adult L2 Acute Lymphoblastic...United States
-
National Cancer Institute (NCI)CompletedB-cell Adult Acute Lymphoblastic Leukemia | Acute Undifferentiated Leukemia | Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell... and other conditionsUnited States
-
Autolus LimitedCompletedCD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) (AMELIA)Recurrent Childhood Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | B-cell Acute Lymphoblastic Leukemia | Refractory Childhood Acute Lymphoblastic LeukemiaUnited Kingdom
-
Children's Oncology GroupNational Cancer Institute (NCI); ImmunoGen, Inc.WithdrawnRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Recurrent Mixed Phenotype Acute Leukemia | Refractory Mixed Phenotype Acute Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent...
-
University of BirminghamAstraZeneca; Cancer Research UKTerminatedAcute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Adult | Acute Lymphoblastic Leukemia RecurrentUnited Kingdom, Denmark, Netherlands
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Graft Versus Host Disease | B-cell Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic Leukemia | Non-T, Non-B Childhood Acute Lymphoblastic LeukemiaUnited States
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinRecruitingAcute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia Recurrent | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved RemissionUnited States
-
University College, LondonNot yet recruitingAcute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Adult | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved Remission
-
Therapeutic Advances in Childhood Leukemia ConsortiumEnzon Pharmaceuticals, Inc.TerminatedLymphoblastic Leukemia, Acute, Childhood | Leukemia, Lymphoblastic, Acute | Lymphoblastic Leukemia, Acute | Leukemia, Lymphoblastic, Acute, T CellUnited States, Australia
Clinical Trials on ABT-751
-
M.D. Anderson Cancer CenterCompletedHematological MalignanciesUnited States
-
AbbottCompleted
-
AbbottCompleted
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)TerminatedABT-751 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone TherapyProstate CancerUnited States
-
National Institutes of Health Clinical Center (CC)National Cancer Institute (NCI)CompletedSarcoma | Kidney Cancer | Unspecified Childhood Solid Tumor, Protocol Specific | Ovarian Cancer | Brain and Central Nervous System Tumors | Neuroblastoma | Liver Cancer | Extragonadal Germ Cell Tumor | Childhood Germ Cell TumorUnited States
-
AbbottCompletedNon-Small Cell Lung CancerUnited States
-
AbbottCompletedBreast CancerUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Neuroblastoma | Disseminated NeuroblastomaUnited States, Canada
-
Konstantin DragnevAbbottTerminatedLung Cancer | Non Small Cell Lung CancerUnited States
-
AbbottTerminatedNon-Small Cell Lung Cancer | Lung CancerUnited States, Canada, Ireland, United Kingdom